BUZZ-Akamai Technologies shares fall after announcing $2.2 billion convertible bond offering
路透社2026/11/09 12:23November 9 - ** Cloud services company Akamai Technologies (AKAM.O) saw its shares fall 7.3% to $77 in pre-market trading after reports that the company plans to raise funds
** AKAM announced it will privately issue two tranches of $1.1 billion each in convertible bonds (link), with one tranche maturing on November 15, 2028, and the other on November 15, 2031
** The company plans to use the net proceeds from this offering to repay part of its outstanding $1.15 billion convertible bonds with a coupon rate of 0.375% maturing in 2027 upon maturity, pay cash due as a result of early conversion of the 2027 convertible bonds, and fund capital expenditures for its cloud infrastructure services business
** The company also plans to use part of the raised funds to cover the costs of convertible bond hedge transactions
** Based in Cambridge, Massachusetts, AKAM has a market capitalization of about $12 billion
** As of Friday's close, the company's stock was down about 5% year-to-date, while the S&P 500 Technology Index (.SPLRCT) was up about 11% and the Nasdaq Index (.IXIC) was up nearly 6%
** According to LSEG data, the average rating from 25 analysts is "buy"; the median price target is $120, down from $155.39 a month ago
(To assist non-English speakers, Reuters has automated the translation of its reports into several additional languages. Due to possible errors in automated translation or the lack of required context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for reader convenience. Reuters accepts no liability for any damage or loss arising from the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Zura Bio shares plummet after mid-stage trial failure of skin disease drug

BUZZ – US Stock Market Updates: Nvidia, Genmab, Eli Lilly
